<DOC>
	<DOCNO>NCT00983424</DOCNO>
	<brief_summary>The purpose research study evaluate safety therapy nab-paclitaxel CsA addition Cyclosporine A ( CsA ) nab-paclitaxel help stop cancer cell well well nab-paclitaxel alone .</brief_summary>
	<brief_title>Cyclosporine A Combination With Nab-Paclitaxel Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>Treatment metastatic breast cancer commonly involve use chemotherapy drug nab-paclitaxel . Nab-paclitaxel special preparation paclitaxel inside protein layer albumin . Other study show Cyclosporine A ( CsA ) may block progression advance breast cancer . The combination nab-paclitaxel CsA consider investigational mean approve US Food Drug Administration , FDA . Participants study receive nab-paclitaxel vein arm weekly 3 week 4 , outpatient clinic . On day first infusion nab-paclitaxel , participant begin take CsA tablet twice day mouth . Participants continue receive study treatment long tumor responds . If tumor respond participant experience severe side effect study treatment , remove study offer therapy , appropriate .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Inclusion Criteria Female male patient adenocarcinoma breast metastatic disease . Patients may evaluable measurable disease . Age &gt; 18 year . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Able swallow retain oral medication . Exclusion Criteria Patients major surgery , hormonal therapy ( replacement ) , chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study patient recover adverse event due agent administer 4 week earlier . Prior nabpaclitaxel allow . Patients may receive investigational agent receive concurrent anticancer therapy . Patients uncontrolled brain metastasis leptomeningeal disease active neurologic impairment . History allergic reaction attribute compound similar chemical biologic composition Cyclosporine A nabpaclitaxel . Pregnant lactating ( Cyclosporine A excrete breast milk ) females Patients GI tract disease result inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's , ulcerative colitis ) . HIVpositive patient exclude since Cyclosporine A may result immunosuppression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>